Fundraising Fox

Scribe Therapeutics

NASDAQ: SCTX

Berkeley, US · Founded 2017 · Delaware corporation · 6 known investors

scribetx.com ↗

Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.

BiotechDeep TechHealthtechMedical Devicesin /scribe-therapeutics@scribetx

Founders & leadership

BO
Benjamin OakesFounder & CEO
JA
Jennifer A. Doudna, PhDCo-founder, Scientific Advisor
BL
Benjamin L. Oakes, PhDCo-founder, President and CEO
DF
David F. Savage, PhDCo-founder, Scientific Advisor
BS
Brett Staahl, PhDCo-founder, VP of External Innovation
VP
Vijay PandeDirector
CG
Carl GordonDirector
BA
Behzad AghazadehDirector

Investors · 6

Andreessen Horowitz✓ verifiedMenlo Park · $500K – $50M
OrbiMed✓ verifiedNew York · $1M – $75M
Avoro Capital AdvisorsNew York
Menlo VenturesSan Francisco · $1M – $20M
Avoro VenturesreportedNew York
RA CapitalreportedBoston

Reported raises · per SEC filings

Form D private placements
▶$100MraisedApr 2021 · 19 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin OakesExecutive Officer, Director
  • Vijay PandeDirector
  • Carl GordonDirector
  • Behzad AghazadehDirector
Offering amount
$100M
Amount sold
$100M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news